Biopharmaceutical developers are increasingly using synthetic control arms generated from historical patient registries and real-world health data. This methodology minimizes the required number of physical placebo participants, particularly in oncology and rare disease clinical trials.
Regulatory Acceptance and Cost Efficiency
Health regulatory agencies have begun accepting synthetic control data to support supplemental drug applications. Industry benchmarks indicate that integrated synthetic control models can reduce Phase II trial costs by up to 30% while significantly accelerating recruitment schedules.